Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 7Active not recruiting 3Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 7NET 4Gastrointestinal 4Endocrine 4Thoracic 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 5Urogenital Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Metastatic Castration-Resistant Prostate Cancer 1

Interventions

Magnetic Resonance Spectroscopy 87Specimen Handling 76pembrolizumab 74enzalutamide 57Radiosurgery 57Radiotherapy 51Docetaxel 50Androgen Antagonists 48Gemcitabine 43Nivolumab 40darolutamide 39Prednisone 35Abiraterone Acetate 33enfortumab vedotin 32Biopsy 31Cisplatin 30Carboplatin 29apalutamide 28Standard of Care 28cabozantinib 27Pluvicto 27abiraterone 26Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 23X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Lutetium × Genitourinary × Clear all
NCT05803941 2026-06-04

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Novartis

Phase 4 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT06517719 2026-06-01

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Novartis

Recruiting
500 enrolled
Genitourinary

Prostatic Neoplasms

NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
520 enrolled
Genitourinary

Prostatic Neoplasms

NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT06531499 2025-12-31

RADIODOSE

Novartis

Phase 1 Recruiting
106 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting
3,360 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT06449781 2025-02-10

PSMA-ADJUVO

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡